특히 최근 신약에 대한 안전성 논란, 기술이전 계약 체결·해지, 임상실패에 따른 주가 급변으로 투자자 피해가 우려된다.
In particular, there is a concern that damage to investors is due to the recent controversy over the safety of new drugs, the signing and termination of technological transfer contracts, and the rapid change in stock prices due to clinical failures.